323 related articles for article (PubMed ID: 32474650)
1. Efficacy of teriparatide compared with risedronate on FRAX
Body JJ; Marin F; Kendler DL; Zerbini CAF; López-Romero P; Möricke R; Casado E; Fahrleitner-Pammer A; Stepan JJ; Lespessailles E; Minisola S; Geusens P
Osteoporos Int; 2020 Oct; 31(10):1935-1942. PubMed ID: 32474650
[TBL] [Abstract][Full Text] [Related]
2. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.
Kendler DL; Marin F; Zerbini CAF; Russo LA; Greenspan SL; Zikan V; Bagur A; Malouf-Sierra J; Lakatos P; Fahrleitner-Pammer A; Lespessailles E; Minisola S; Body JJ; Geusens P; Möricke R; López-Romero P
Lancet; 2018 Jan; 391(10117):230-240. PubMed ID: 29129436
[TBL] [Abstract][Full Text] [Related]
3. Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial.
Minisola S; Marin F; Kendler DL; Geusens P; Zerbini CAF; Russo LA; Casado E; Fahrleitner-Pammer A; Stepan JJ; Lespessailles E; Moericke R; Bagur A; Lakatos P; López-Romero P; Body JJ
Arch Osteoporos; 2019 Jan; 14(1):10. PubMed ID: 30659410
[TBL] [Abstract][Full Text] [Related]
4. FRAX and the effect of teriparatide on vertebral and non-vertebral fracture.
Harvey NC; Kanis JA; Odén A; Burge RT; Mitlak BH; Johansson H; McCloskey EV
Osteoporos Int; 2015 Nov; 26(11):2677-84. PubMed ID: 26092063
[TBL] [Abstract][Full Text] [Related]
5. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.
Hadji P; Zanchetta JR; Russo L; Recknor CP; Saag KG; McKiernan FE; Silverman SL; Alam J; Burge RT; Krege JH; Lakshmanan MC; Masica DN; Mitlak BH; Stock JL
Osteoporos Int; 2012 Aug; 23(8):2141-50. PubMed ID: 22159672
[TBL] [Abstract][Full Text] [Related]
6. Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trial.
Kendler DL; Marin F; Geusens P; López-Romero P; Lespessailles E; Body JJ; Minisola S
Bone; 2020 Jan; 130():115113. PubMed ID: 31654779
[TBL] [Abstract][Full Text] [Related]
7. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
8. Distribution of Prevalent and Incident Vertebral Fractures and Their Association with Bone Mineral Density in Postmenopausal Women in the Teriparatide Versus Risedronate VERO Clinical Trial.
Geusens P; Kendler DL; Fahrleitner-Pammer A; López-Romero P; Marin F
Calcif Tissue Int; 2020 Jun; 106(6):646-654. PubMed ID: 32157334
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX.
Harvey NC; Kanis JA; Odén A; Nakamura T; Shiraki M; Sugimoto T; Kuroda T; Johansson H; McCloskey EV
Osteoporos Int; 2015 Sep; 26(9):2347-53. PubMed ID: 26092062
[TBL] [Abstract][Full Text] [Related]
10. Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability.
McCloskey EV; Fitzpatrick LA; Hu MY; Williams G; Kanis JA
Arch Osteoporos; 2019 Feb; 14(1):15. PubMed ID: 30719589
[TBL] [Abstract][Full Text] [Related]
11. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
[TBL] [Abstract][Full Text] [Related]
12. Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial.
Geusens P; Marin F; Kendler DL; Russo LA; Zerbini CA; Minisola S; Body JJ; Lespessailles E; Greenspan SL; Bagur A; Stepan JJ; Lakatos P; Casado E; Moericke R; López-Romero P; Fahrleitner-Pammer A
J Bone Miner Res; 2018 May; 33(5):783-794. PubMed ID: 29329484
[TBL] [Abstract][Full Text] [Related]
13. Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study.
McCloskey EV; Johansson H; Harvey NC; Lorentzon M; Shi Y; Kanis JA
Osteoporos Int; 2021 Aug; 32(8):1601-1608. PubMed ID: 33537844
[TBL] [Abstract][Full Text] [Related]
14. CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
Albert SG; Reddy S
Endocr Pract; 2017 Jul; 23(7):841-856. PubMed ID: 28448754
[TBL] [Abstract][Full Text] [Related]
15. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
16. Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.
Zhang L; Pang Y; Shi Y; Xu M; Xu X; Zhang J; Ji L; Zhao D
Menopause; 2015 Sep; 22(9):1021-5. PubMed ID: 25944523
[TBL] [Abstract][Full Text] [Related]
17. An evaluation of the Fracture Risk Assessment Tool (FRAX®) as an indicator of treatment efficacy: the effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX®.
Kaufman JM; Palacios S; Silverman S; Sutradhar S; Chines A
Osteoporos Int; 2013 Oct; 24(10):2561-9. PubMed ID: 23595562
[TBL] [Abstract][Full Text] [Related]
18. A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05.
Hagino H; Sugimoto T; Tanaka S; Sasaki K; Sone T; Nakamura T; Soen S; Mori S
Osteoporos Int; 2021 Nov; 32(11):2301-2311. PubMed ID: 34002252
[TBL] [Abstract][Full Text] [Related]
19. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
[TBL] [Abstract][Full Text] [Related]
20. Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis.
Watts NB; Hattersley G; Fitzpatrick LA; Wang Y; Williams GC; Miller PD; Cosman F
Osteoporos Int; 2019 Jun; 30(6):1187-1194. PubMed ID: 30899994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
